Handelsavisen
prelaunch
Companies Healthcare LABS.JK
LA
LABS.JK IDX (Jakarta) Medical Equipment, Supplies & Distribution

PT UBC Medical Indonesia Tbk

$176,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
ROE
Net margin
Debt / equity
0,31
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

PT UBC Medical Indonesia Tbk provides medical equipment, supplies, and distribution services in Indonesia.

Business. PT UBC Medical Indonesia Tbk (LABS.JK) is a healthcare company engaged in the medical equipment, supplies, and distribution industry. The firm operates primarily through the sale of medical products and is headquartered in Indonesia. It is listed on the Indonesia Stock Exchange (IDX) under the ticker symbol LABS.JK. Specific details regarding operating segments or geographic revenue breakdowns are not provided.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning LABS.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to LABS.JK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    PT UBC Medical Indonesia Tbk (LABS.JK) is a healthcare company engaged in the medical equipment, supplies, and distribution industry. The firm operates primarily through the sale of medical products and is headquartered in Indonesia. It is listed on the Indonesia Stock Exchange (IDX) under the ticker symbol LABS.JK. Specific details regarding operating segments or geographic revenue breakdowns are not provided.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    The company maintains a relatively strong capital structure, with a debt-to-equity ratio of 0.31, indicating a conservative leverage position. However, its liquidity position is assessed as medium, with a current ratio of 1.94, suggesting the company has sufficient short-term assets to cover its liabilities, but not with a large buffer. The company reported negative net cash, as operating cash flow was -9,276,646,290 IDR, while free cash flow was 3,238,761,210 IDR. This suggests that capital expenditures, which amounted to -3,180,165,240 IDR, were partially offset by positive free cash flow.

    Profitability metrics are not explicitly provided, but the company's capital structure and liquidity position suggest a relatively stable financial foundation. The debt-to-equity ratio of 0.31 is below the industry median, indicating a lower reliance on debt financing compared to peers. The company's free cash flow generation, despite negative operating cash flow, suggests that it is managing its capital expenditures effectively.

    The company's geographic exposure is concentrated in Indonesia, as it is a domestic player in the medical equipment and supplies market. There is no indication of significant international operations or revenue diversification. The company's revenue concentration in a single country may expose it to local economic and regulatory risks.

    The company's growth trajectory is not explicitly outlined in the available data, but the negative operating cash flow and capital expenditures suggest that it may be investing in expansion or modernization. The free cash flow of 3,238,761,210 IDR indicates that the company is generating some cash from operations, which could support future growth initiatives.

    The company's risk profile includes a medium liquidity risk, as it has a current ratio of 1.94, which is sufficient but not robust. The risk of dilution is assessed as low, with no immediate pressure for share issuance. The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.31, which reduces the risk of financial distress.

    Recent events and filings do not provide specific details on the company's strategic initiatives or financial performance beyond the disclosed financials. The company's 10-K or equivalent filings would provide more detailed insights into its operations and risk factors.

    Key takeaways
    • The company maintains a conservative debt-to-equity ratio of 0.31, indicating a strong capital structure.
    • Free cash flow of 3,238,761,210 IDR suggests the company is generating cash from operations despite negative operating cash flow.
    • The company's liquidity position is assessed as medium, with a current ratio of 1.94.
    • The company's operations are concentrated in Indonesia, which may expose it to local economic and regulatory risks.
    • The risk of dilution is low, with no immediate pressure for share issuance.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation FY

    Market price
    $176,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $69.29B
    Net cash
    -$21.41B
    Current ratio
    1.9
    Debt / equity
    0.3
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    D/E0,31Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • PT UBC Medical Indonesia Tbk Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    LABS.JKCanonical
    IDX (Jakarta) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage